Which has higher valuation & earnings, RGEN or TECH?

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Repligen $738.26M 12.75 $48.89M $0.73 228.53 Bio-Techne $1.22B 9.33 $73.40M $1.15 62.96

Is RGEN or TECH more profitable?

Bio-Techne has a net margin of 14.97% compared to Repligen's net margin of 5.29%. Bio-Techne's return on equity of 13.23% beat Repligen's return on equity. Company Net Margins Return on Equity Return on Assets Repligen 5.29% 5.30% 3.79% Bio-Techne 14.97% 13.23% 10.61%

Does the media favor RGEN or TECH?

In the previous week, Bio-Techne had 15 more articles in the media than Repligen. MarketBeat recorded 21 mentions for Bio-Techne and 6 mentions for Repligen. Repligen's average media sentiment score of 1.34 beat Bio-Techne's score of 0.88 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Techne 7 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer A or RGEN?

In the previous week, Agilent Technologies had 17 more articles in the media than Repligen. MarketBeat recorded 23 mentions for Agilent Technologies and 6 mentions for Repligen. Agilent Technologies' average media sentiment score of 1.41 beat Repligen's score of 1.34 indicating that Agilent Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agilent Technologies 20 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, RGEN or BIO?

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Repligen $738.26M 12.75 $48.89M $0.73 228.53 Bio-Rad Laboratories $2.58B 3.68 $759.90M $8.25 43.10

Does the media favor RGEN or BIO?

In the previous week, Repligen and Repligen both had 6 articles in the media. Repligen's average media sentiment score of 1.34 beat Bio-Rad Laboratories' score of 1.12 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Rad Laboratories 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, DHR or RGEN?

Danaher has higher revenue and earnings than Repligen. Danaher is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Danaher $24.57B 5.79 $3.61B $5.63 35.97 Repligen $738.26M 12.75 $48.89M $0.73 228.53

Is DHR or RGEN more profitable?

Danaher has a net margin of 15.95% compared to Repligen's net margin of 5.29%. Danaher's return on equity of 11.04% beat Repligen's return on equity. Company Net Margins Return on Equity Return on Assets Danaher 15.95% 11.04% 6.81% Repligen 5.29% 5.30% 3.79%

Does the media refer more to DHR or RGEN?

In the previous week, Danaher had 4 more articles in the media than Repligen. MarketBeat recorded 10 mentions for Danaher and 6 mentions for Repligen. Repligen's average media sentiment score of 1.34 beat Danaher's score of 0.68 indicating that Repligen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Danaher 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Repligen 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MTD or RGEN?

In the previous week, Mettler-Toledo International had 3 more articles in the media than Repligen. MarketBeat recorded 9 mentions for Mettler-Toledo International and 6 mentions for Repligen. Mettler-Toledo International's average media sentiment score of 1.46 beat Repligen's score of 1.34 indicating that Mettler-Toledo International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mettler-Toledo International 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Repligen (RGEN) Competitors

$166.83 -0.66 (-0.39%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$169.56 +2.72 (+1.63%)

As of 08/14/2026 07:34 PM Eastern

Compare

RGEN vs. TECH, A, BIO, DHR, and MTD

Should you buy Repligen stock or one of its competitors? Repligen's main competitors and comparable companies include Bio-Techne (TECH), Agilent Technologies (A), Bio-Rad Laboratories (BIO), Danaher (DHR), and Mettler-Toledo International (MTD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Repligen compare to Bio-Techne?

Repligen (NASDAQ:RGEN) and Bio-Techne (NASDAQ:TECH) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

In the previous week, Bio-Techne had 15 more articles in the media than Repligen. MarketBeat recorded 21 mentions for Bio-Techne and 6 mentions for Repligen. Repligen's average media sentiment score of 1.34 beat Bio-Techne's score of 0.88 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Techne	7 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bio-Techne has a net margin of 14.97% compared to Repligen's net margin of 5.29%. Bio-Techne's return on equity of 13.23% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	5.29%	5.30%	3.79%
Bio-Techne	14.97%	13.23%	10.61%

97.6% of Repligen shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 0.6% of Repligen shares are owned by insiders. Comparatively, 1.3% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	12.75	$48.89M	$0.73	228.53
Bio-Techne	$1.22B	9.33	$73.40M	$1.15	62.96

Repligen has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

Repligen presently has a consensus target price of $166.43, suggesting a potential downside of 0.24%. Bio-Techne has a consensus target price of $68.92, suggesting a potential downside of 4.80%. Given Repligen's stronger consensus rating and higher probable upside, equities research analysts plainly believe Repligen is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Bio-Techne	1 Sell rating(s)	14 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06

Summary

Bio-Techne beats Repligen on 10 of the 17 factors compared between the two stocks.

How does Repligen compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Repligen (NASDAQ:RGEN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Agilent Technologies currently has a consensus price target of $160.24, indicating a potential upside of 7.87%. Repligen has a consensus price target of $166.43, indicating a potential downside of 0.24%. Given Agilent Technologies' higher possible upside, analysts clearly believe Agilent Technologies is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

87.4% of Agilent Technologies shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 0.2% of Agilent Technologies shares are owned by insiders. Comparatively, 0.6% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Agilent Technologies has a beta of 1.25, suggesting that its share price is 25% more volatile than the broader market. Comparatively, Repligen has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

In the previous week, Agilent Technologies had 17 more articles in the media than Repligen. MarketBeat recorded 23 mentions for Agilent Technologies and 6 mentions for Repligen. Agilent Technologies' average media sentiment score of 1.41 beat Repligen's score of 1.34 indicating that Agilent Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	20 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agilent Technologies has a net margin of 19.55% compared to Repligen's net margin of 5.29%. Agilent Technologies' return on equity of 24.33% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.55%	24.33%	12.99%
Repligen	5.29%	5.30%	3.79%

Agilent Technologies has higher revenue and earnings than Repligen. Agilent Technologies is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$7.23B	5.80	$1.30B	$4.98	29.83
Repligen	$738.26M	12.75	$48.89M	$0.73	228.53

Summary

Agilent Technologies beats Repligen on 11 of the 17 factors compared between the two stocks.

How does Repligen compare to Bio-Rad Laboratories?

Repligen (NASDAQ:RGEN) and Bio-Rad Laboratories (NYSE:BIO) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Bio-Rad Laboratories has a net margin of 8.59% compared to Repligen's net margin of 5.29%. Repligen's return on equity of 5.30% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	5.29%	5.30%	3.79%
Bio-Rad Laboratories	8.59%	3.54%	2.48%

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	12.75	$48.89M	$0.73	228.53
Bio-Rad Laboratories	$2.58B	3.68	$759.90M	$8.25	43.10

Repligen has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Repligen presently has a consensus price target of $166.43, suggesting a potential downside of 0.24%. Bio-Rad Laboratories has a consensus price target of $343.33, suggesting a potential downside of 3.44%. Given Repligen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Repligen is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Bio-Rad Laboratories	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

97.6% of Repligen shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 0.6% of Repligen shares are owned by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Repligen and Repligen both had 6 articles in the media. Repligen's average media sentiment score of 1.34 beat Bio-Rad Laboratories' score of 1.12 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Rad Laboratories	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Repligen beats Bio-Rad Laboratories on 10 of the 16 factors compared between the two stocks.

How does Repligen compare to Danaher?

Danaher (NYSE:DHR) and Repligen (NASDAQ:RGEN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

In the previous week, Danaher had 4 more articles in the media than Repligen. MarketBeat recorded 10 mentions for Danaher and 6 mentions for Repligen. Repligen's average media sentiment score of 1.34 beat Danaher's score of 0.68 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Danaher	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Repligen	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Danaher presently has a consensus price target of $228.91, indicating a potential upside of 13.04%. Repligen has a consensus price target of $166.43, indicating a potential downside of 0.24%. Given Danaher's higher probable upside, analysts plainly believe Danaher is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Danaher	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.84
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

Danaher has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Repligen has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

Danaher has a net margin of 15.95% compared to Repligen's net margin of 5.29%. Danaher's return on equity of 11.04% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Danaher	15.95%	11.04%	6.81%
Repligen	5.29%	5.30%	3.79%

Danaher has higher revenue and earnings than Repligen. Danaher is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Danaher	$24.57B	5.79	$3.61B	$5.63	35.97
Repligen	$738.26M	12.75	$48.89M	$0.73	228.53

79.1% of Danaher shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 10.8% of Danaher shares are owned by company insiders. Comparatively, 0.6% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Danaher beats Repligen on 10 of the 17 factors compared between the two stocks.

How does Repligen compare to Mettler-Toledo International?

Mettler-Toledo International (NYSE:MTD) and Repligen (NASDAQ:RGEN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Mettler-Toledo International has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Repligen has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

Mettler-Toledo International has higher revenue and earnings than Repligen. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mettler-Toledo International	$4.03B	7.05	$869.19M	$44.43	31.90
Repligen	$738.26M	12.75	$48.89M	$0.73	228.53

95.1% of Mettler-Toledo International shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 0.7% of Mettler-Toledo International shares are held by company insiders. Comparatively, 0.6% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Mettler-Toledo International had 3 more articles in the media than Repligen. MarketBeat recorded 9 mentions for Mettler-Toledo International and 6 mentions for Repligen. Mettler-Toledo International's average media sentiment score of 1.46 beat Repligen's score of 1.34 indicating that Mettler-Toledo International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mettler-Toledo International	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mettler-Toledo International presently has a consensus price target of $1,461.27, indicating a potential upside of 3.10%. Repligen has a consensus price target of $166.43, indicating a potential downside of 0.24%. Given Mettler-Toledo International's higher possible upside, equities analysts clearly believe Mettler-Toledo International is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mettler-Toledo International	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

Mettler-Toledo International has a net margin of 21.91% compared to Repligen's net margin of 5.29%. Repligen's return on equity of 5.30% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mettler-Toledo International	21.91%	-1,212.14%	25.11%
Repligen	5.29%	5.30%	3.79%

Summary

Mettler-Toledo International beats Repligen on 10 of the 17 factors compared between the two stocks.

Get Repligen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGEN vs. The Competition

Export

Metric	Repligen	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.45B	$9.65B	$7.04B	$13.07B
Dividend Yield	N/A	1.46%	2.57%	10.45%
P/E Ratio	228.53	60.31	270.17	25.33
Price / Sales	12.75	105.52	574.42	74.81
Price / Cash	49.02	26.25	70.48	50.90
Price / Book	4.46	37.50	12.91	6.25
Net Income	$48.89M	$56.66B	$3.45B	$347.82M
7 Day Performance	1.79%	0.26%	1.15%	1.08%
1 Month Performance	12.68%	1.35%	1.37%	0.82%
1 Year Performance	34.16%	17.32%	62.52%	20.99%

Repligen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGEN Repligen	3.1659 of 5 stars	$166.83 -0.4%	$166.43 -0.2%	+31.7%	$9.45B	$738.26M	228.53	2,000	Positive News Analyst Upgrade
TECH Bio-Techne	3.1678 of 5 stars	$72.12 -0.2%	$68.08 -5.6%	+34.7%	$11.29B	$1.21B	104.52	3,100	News Coverage Earnings Report Dividend Announcement Analyst Downgrade
A Agilent Technologies	4.5489 of 5 stars	$148.42 +1.7%	$159.35 +7.4%	+24.9%	$41.23B	$6.95B	29.80	18,100	News Coverage Positive News Analyst Forecast
BIO Bio-Rad Laboratories	2.0164 of 5 stars	$353.82 +0.4%	$343.33 -3.0%	+23.9%	$9.43B	$2.58B	42.89	7,450	Analyst Upgrade
DHR Danaher	4.2731 of 5 stars	$208.92 +2.0%	$228.91 +9.6%	-3.8%	$143.94B	$24.57B	37.11	60,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGEN) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Repligen (RGEN) Competitors

RGEN vs. TECH, A, BIO, DHR, and MTD

How does Repligen compare to Bio-Techne?

Summary

How does Repligen compare to Agilent Technologies?

Summary

How does Repligen compare to Bio-Rad Laboratories?

Summary

How does Repligen compare to Danaher?

Summary

How does Repligen compare to Mettler-Toledo International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGEN vs. The Competition

Repligen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Repligen (RGEN) Competitors

RGEN vs. TECH, A, BIO, DHR, and MTD

How does Repligen compare to Bio-Techne?

Does the media favor RGEN or TECH?

Is RGEN or TECH more profitable?

Do institutionals and insiders have more ownership in RGEN or TECH?

Which has higher valuation & earnings, RGEN or TECH?

Which has more risk & volatility, RGEN or TECH?

Do analysts prefer RGEN or TECH?

Summary

How does Repligen compare to Agilent Technologies?

Do analysts recommend A or RGEN?

Do institutionals & insiders believe in A or RGEN?

Which has more risk and volatility, A or RGEN?

Does the media prefer A or RGEN?

Is A or RGEN more profitable?

Which has higher earnings & valuation, A or RGEN?

Summary

How does Repligen compare to Bio-Rad Laboratories?

Is RGEN or BIO more profitable?

Which has stronger earnings & valuation, RGEN or BIO?

Which has more risk & volatility, RGEN or BIO?

Do analysts prefer RGEN or BIO?

Do institutionals and insiders have more ownership in RGEN or BIO?

Does the media favor RGEN or BIO?

Summary

How does Repligen compare to Danaher?

Does the media refer more to DHR or RGEN?

Do analysts rate DHR or RGEN?

Which has more risk and volatility, DHR or RGEN?

Is DHR or RGEN more profitable?

Which has preferable valuation and earnings, DHR or RGEN?

Do institutionals and insiders believe in DHR or RGEN?

Summary

How does Repligen compare to Mettler-Toledo International?

Which has more volatility and risk, MTD or RGEN?

Which has better valuation and earnings, MTD or RGEN?

Do insiders & institutionals believe in MTD or RGEN?

Does the media refer more to MTD or RGEN?

Do analysts prefer MTD or RGEN?

Is MTD or RGEN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGEN vs. The Competition

Repligen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools